62-Year-Old Patient with a Leg Wound Post Heart Transplant

Presented by Barbara D. Alexander, MD

*Image is representative and is not of the actual patient.

Case Presentation

A 62-year-old man, who was 6 months post heart transplant complicated by steroid-induced diabetes, hit his leg on a tree branch while golfing. The site of the initial wound became progressively erythematous and painful over the next 24 hours, for which he sought care from his physician, who prescribed oral cephalexin.

By day 7 following the initial trauma, and despite compliance with the antibiotic, he developed fever. He also reported that the wound at the primary injury site had enlarged significantly, was developing a black center, and that the redness and pain were continuing to spread up and down his leg.

He was admitted to the hospital for further assessment. The wound at time of presentation is shown in Figure 1.

Figure 1. Left lower extremity with a 6-cm x 7-cm wound with central eschar and surrounding pallor and erythema. Image courtesy of Barbara D. Alexander, MD.

What is a critical next step in the diagnosis of this infection?

  1. Send a swab of the base of the wound for fungal culture.
  2. Obtain a swab for Herpes Simplex Virus polymerase chain reaction (PCR) testing.
  3. Send a fungal blood culture.
  4. Obtain a tissue biopsy from the edge of the wound for examination and culture.

Correct answer: 4

Cutaneous inoculation of fungi as a consequence of trauma is a well-described mode of acquiring invasive fungal infections. In immunocompetent hosts, mononuclear and polymorphonuclear phagocytes normally serve as a primary host defense against cutaneously inoculated spores. However, in the immunocompromised host, the spores are able to germinate, and the hyphae invade surrounding tissues.1 Infarction and necrosis of host tissue ensue as the hyphae invade blood vessels. The differential for a patient presenting with a necrotic eschar accompanied by surrounding erythema and induration following trauma should include invasive cutaneous fungal infection, particularly for immunosuppressed patients and those with diabetes.2 The diagnosis of mucormycosis infections requires a high degree of suspicion, awareness of host factors, and appropriate evaluation.

Answer 1 is incorrect. Swabs are inferior to tissue and fluid for recovery of fungi. Further, swabbing the base of the wound runs the risk of picking up wound colonizers and environmental contaminants rather than the actual pathogen causing disease in the deeper tissues.3

Answer 2 is incorrect. Viral infections such as herpes simplex and varicella zoster would more classically present with vesicular lesions. Further, reactivation of herpes viruses would be less likely to occur at the actual site of the trauma. However, bacterial infection is certainly on the differential in such cases.

Answer 3 is incorrect. And while advances in blood culture systems (e.g., specialized broth media, automated and continuous monitoring platforms, etc.) have improved recovery of some fungi including Candida from blood, blood cultures are typically not positive in cases of invasive aspergillosis and mucormycosis, even in the face of disseminated disease.

Visualization of fungal elements in tissue remains the cornerstone for diagnosing invasive mycoses: however, isolation and identification of the infecting organism are required for a precise diagnosis.

Case continued

Blood cultures were collected and the patient was started empirically on intravenous (IV) vancomycin and piperacillin-tazobactam. A magnetic resonance image (MRI) scan of the leg showed diffuse cellulitis and myositis, but no changes to suggest osteomyelitis.

However, given the appearance of the wound, he was taken urgently to the operating room for biopsy and debridement wherein the eschar and all “non-viable” tissue were widely excised circumferentially and to the level of the deep fascia. Samples of the subcutaneous tissue and a sample from the periphery of the wound of presumably “viable, uninfected” tissue were submitted for culture and histopathology.

The microbiology laboratory immediately performed a potassium hydroxide (KOH) examination of both the subcutaneous and peripheral rim tissues. Images from the microscopic examination of the peripheral rim tissue are shown in Figure 2.

Figure 2. Potassium Hydroxide with Calcofluor White Stain of tissue viewed under fluorescent microscopy (1000X magnification). Image courtesy of Barbara D. Alexander, MD.

What should the laboratory technologist report?

  1. Fungal elements present.
  2. Septate, fungal hyphae present.
  3. Broad, ribbon-like, sparsely septate fungal hyphae present.
  4. Budding yeast with pseudohyphae present.

Discussion:

Correct Answer: 3 

Direct KOH examination of the tissue specimen shows broad, ribbon-like, hyphae that are approximately 15 µm in diameter with irregular branching and sparse septations. Calcofluor White is a fluorochrome that binds to chitin and β-glucans in fungal cell walls. When the specimen is examined under a fluorescence microscope with ultraviolet filters, the fungal elements fluoresce, making them easier to distinguish from background tissues and other artifacts such as cotton fibers.

Possible answer 1: While a report of ‘fungal elements’ is not incorrect, a more specific description provides critically important information to guide further management of the infection. Specifically, “broad, ribbon-like, sparsely septate fungal hyphae” suggests mucormycosis.4

Answer 2 is incorrect. A hyphomycete-type pathogen such as Aspergillus, Scedosporium, or Fusarium, wherein the hyphae tend to be smaller (3-5 µm in diameter) with regular septations present, was not seen.4

Answer 4 is incorrect. No budding yeast or pseudohyphae are seen (suggesting Candida), making this response incorrect.

Case continued

Histopathology ultimately confirmed inflammatory debris and fibroconnective tissue with acute inflammation and necrosis and showed numerous broad, fungal hyphae infiltrating the tissue.

Timely diagnosis is essential to optimizing outcomes in mucormycosis because mortality increases with delays in diagnosis and initiation of therapy.5,6,7 

Liposomal amphotericin B was immediately administered intravenously and, given the presence of hyphae in the tissue from what was presumed to be the “clear margin”, the patient was returned to the operating room for wider debridement the following day. KOH examination of the tissues removed during the repeat debridement was negative for fungi. After 24 hours of incubation, cultures of tissue from the initial debridement grew mold (Figure 3a), ultimately identified phenotypically as Rhizopus species.

Figure 3. Mold growing from tissue on fungal media after 24 hours (3a) and 48 hours (3b). Images courtesy of Barbara D. Alexander, MD.

What additional testing would help further guide management in this case?

  1. Perform phenotypic susceptibility testing to isavuconazole and posaconazole.
  2. Send tissue for PCR/next generation sequencing to confirm the infecting pathogen.
  3. Send the fungal isolate to a reference laboratory for molecular identification to species level.
  4. Send plasma for beta-D-glucan test.

Discussion:

Correct answer: 1

Guidelines for management of mucormycosis are based on consensus recommendations.8,9 Amphotericin B and amphotericin B-based lipid formulations remain the agents of choice for empiric management of mucormycosis.8,9 However, amphotericin B has notorious toxicities and requires IV administration. While posaconazole and isavuconazole are available orally with fewer toxicities, their in vitro activity against the Mucorales is not predictable.10,11  While there are no established clinical breakpoints for the Mucorales for any of the antifungal drugs, standardized susceptibility testing to isavuconazole and posaconazole could provide insight regarding the level of activity for each drug against this patient’s specific pathogen, thereby guiding choice of step-down therapy.

Diagnosis of mucormycosis is typically made based on a combination of clinical, imaging, culture, and histopathologic findings.

Grinding tissue for culture risks disrupting the fragile and sparsely septate hyphae, resulting in no viable cells. Instead, tissue should be finely minced and placed directly on fungal media.4  When recovered, these fungi grow rapidly on laboratory media, producing abundant cottony colonies (Figure 3b). Identification is based on their sporangial structures.8 However, culture is only approximately 50% sensitive for their recovery, even in microscopically positive samples.  Thus, molecular-based assays for detection of Mucorales DNA in culture-negative specimens are emerging as a key means of identifying the pathogen, particularly when the organism does not grow in culture.

Answers 2 and 3 are incorrect. In the current case, the fungal pathogen was recovered in culture, thus extraction of DNA and sequencing for identification would add unnecessary expense. Identification of Rhizopus to species level also does not offer further information to guide management.

Answer 4 is incorrect. The non-invasive blood-based beta-D-glucan and galactomannan tests are not helpful in the diagnosis of mucormycosis because Mucorales species lack significant quantities of these polysaccharides in their cell walls.9

There is growing interest in the utility of molecular testing to noninvasively detect Mucorales DNA, but such testing is not approved by the United States Food and Drug Administration at this time. One prospective trial found the sensitivity and specificity of a serum Mucorales quantitative PCR to be 85.2% and 89.8%, respectively, and the first positive PCR was seen a median of 4 days (interquartile range 0-9 days) before the first positive mycological or histologic specimen in their study.12  Another study retrospectively analyzed archived specimens from hematopoietic stem recipients with invasive pulmonary mold (primarily Aspergillus and Mucorales) infection for the presence of microbial cell-free (mcf) DNA in plasma (Karius Laboratory, Redwood City, CA). The median mcfDNA concentrations were higher in Mucorales compared with Aspergillus cases, and high mcfDNA concentrations at diagnosis (mcfDNA concentrations >4.0 log10 molecules per microliter) were associated with 6-week mortality.13,14 Left to be explained is the variation in fungal DNA concentrations for Aspergillus compared with Mucorales infections. Ultimately, further study is needed to understand the role of molecular testing for diagnosis of Mucorales infections as well as the implications of fungal DNA concentration and kinetics on therapeutic response.

Summary 

Following prompt and aggressive debridement, this patient went on to complete 3 months total liposomal amphotericin B and underwent split-thickness skin grafting with complete response and successful salvage of his leg. Clinicians must consider mucormycosis in the appropriate clinical setting and pursue invasive testing to establish a diagnosis of mucormycosis as early as possible. Communication with microbiology laboratory personnel to coordinate and facilitate tissue examination and culture is key. Further, emergent surgical debridement and directed antifungal therapy are critical to optimizing outcomes.

Resources

    1. Shoham S, Levitz SM. The immune response to fungal infections. Br J Haematol. 2005;129(5):569-582.
    2. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54 Suppl 1:S23-34.
    3. Berkow EL, Sexton DJ, 2023. Specimen collection, transport, and processing: mycology. In Manual of Clinical Microbiology, 13th Edition. Washington, DC: ASM Press; 2023:1-1.
    4. Kelly BT, Pennington KM, Limper AH. Advances in the diagnosis of fungal pneumonias. Expert Rev Respir Med. 2020;14(7):703-714. doi:10.1080/17476348.2020.1753506.
    5. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503-509.
    6. Jeong SJ, Lee JU, Song YG, Lee KH, Lee MJ. Delaying diagnostic procedure significantly increases mortality in patients with invasive mucormycosis. 2015;58(12):746-752.
    7. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012;54(suppl 1):S55-S60.
    8. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis. Clin Microbiol Infect. 2014;20(suppl 3):5-26.
    9. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433-444.
    10. Espinel-Ingroff A, Chakrabarti A, Chowdhary A, et al. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of mucorales. Antimicrob Agents Chemother. 2015;59(3):1745-1750.
    11. Arendrup MC, Jensen RH, Meletiadis J. Vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order. Antimicrob Agents Chemother. 2015;59(12):7735-7742.
    12. Millon L, Caillot D, Berceanu A, Bretagne S, et al. Evaluation of serum Mucorales polymerase chain reaction (PCR) for the diagnosis of Mucormycoses: The MODIMUCOR prospective trial. Clin Infect Dis. 2022;75(5):777-785. doi:10.1093/cid/ciab1066. PMID: 34986227.
    13. Hill JA, Dalai SC, Hong DK, et al. Liquid biopsy for invasive mold infections in hematopoietic cell transplant recipients with pneumonia through next-generation sequencing of microbial cell-free DNA in plasma.Clin Infect Dis. 2021;73(11):e3876-e3883.
    14. Heldman MR et al. Serial quantitation of plasma microbial cell-free DNA before and after diagnosis of pulmonary invasive mold infections after hematopoietic cell transplant. J Infect Dis. 2024;229(2):576-587.
    15. Heldman MR, Ahmed AA, Liu W, Vo A, Keane-Candib J, Stevens-Ayers T, Boeckh M, Blauwkamp TA, Fisher CE, Hill JA. Serial quantitation of plasma microbial cell-free DNA before and after diagnosis of pulmonary invasive mold infections after hematopoietic cell transplant. J Infect Dis. 2024;229(2):576-587. doi:10.1093/infdis/jiad255. PMID: 37405403.

Chair

Ruth Ashbee, PhD

Honorary Principal Clinical Scientist, Mycology Reference Center, Leeds, UK
Visiting Lecturer in the School of Molecular and Cellular Biology at the University of Leeds
Chair, British Society for Medical Mycology Therapeutic Drug Monitoring Guidelines Working Party
Fellow of the European Confederation of Medical Mycology
Leeds, United Kingdom

Faculty

Barbara Alexander, MD

Vice Chief of Transplant/Immunocompromised Host Infectious Diseases Services
Head of Clinical Mycology Laboratory
Professor of Medicine and Pathology
Duke University School of Medicine
Durham, North Carolina, USA

Beatriz L. Gómez, PhD

Professor, School of Medicine
Universidad del Rosario
Bogotá, Colombia

Rita Oladele, PhD

Clinical Microbiologist
Associate Professor and Clinical Consultant at University of Lagos and Lagos University Teaching Hospital
Fellow of the European Confederation of Medical Mycology
Fellow of the Royal College of Pathology
Chair of Pan Africa Mycology Working Group
Lagos, Nigeria

Joy Sarojini Michael, MD FRCPath

Professor & Clinical Microbiologist
Christian Medical College, Vellore, Tamil Nadu, India
Vice Chair of Tamil Nadu State TB Task Force Committee
Tamil Nadu, India

Alida Fe Talento, MD

Researcher and Consultant Microbiologist at Children’s Health Ireland
Clinical Senior Lecturer in the Department of Clinical Microbiology, Trinity College Dublin
Honorary Clinical Associate Professor in the Department of Microbiology at the Royal College of Surgeons
Dublin, Ireland  

Angela M. Tobón, MD

Lecturer-Investigator
Institution of Tropical Medicine
Universidad CES
Medellín, Colombia

Computer System Requirements

To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).

Privacy Policy

Terranova Medica, LLC, and ISHAM are committed to protecting the privacy of those who choose to participate in activities on funguseducationhub.org. The information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of personal information
Terranova Medica, LLC, and ISHAM do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.

For further information, contact Tom Davis by telephone (877-276-4523), or by email (tdavis@terranovamedica.com).

Copyright © 2024 ISHAM, and Terranova Medica, LLC